



(51) International Patent Classification:
G16C 20/50 (2019.01)

(21) International Application Number:
PCT/EP2021/068718

(22) International Filing Date:
06 July 2021 (06.07.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2010679.5 10 July 2020 (10.07.2020) GB

(71) Applicant: **WISTA LABORATORIES LTD.** [SG/SG];
25 Bukit Batok Crescent, The Elitist #06-13, Singapore,
658066 (SG).

(71) Applicant (for MG only): **WISCHIK, Claude Michel**
[GB/GB]; TauRx Therapeutics Ltd., 395 King Street, Ab-
erdeen Aberdeenshire AB24 5RP (GB).

(72) Inventors: **MAZANETZ, Michael Philip**; C/O NovaDa-
ta Solutions Ltd, 15 Monreith Rd., Newlands, Glasgow

G43 2NX (GB). **WISCHIK, Claude Michel**; C/O TauRX
Therapeutics Ltd., 395 King Street, Aberdeen Aberdeenshire
AB24 5RP (GB). **SERPELL, Louise Charlotte**; Demen-
tia Research Group, Sussex Neuroscience, School of Life
Sciences, University of Sussex, Falmer Sussex BN1 9QG
(GB). **STOREY, John Mervyn David**; C/O WisTa Labo-
ratories Ltd, Department of Chemistry, Meston Walk, Old
Aberdeen Aberdeenshire AB24 3UE (GB).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Coun-
terslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,

(54) Title: METHODS OF PROVIDING MODULATORS OF TAU AGGREGATION




Figure 1

(57) Abstract: The present invention relates generally to methods for selecting or designing a compound for modulating the aggregation of a Tau protein. The method comprising using computer- implemented molecular modelling means to compare the three-dimensional structure of a candidate compound with a three-dimensional structure of at least a part of the Tau protein comprising amino acids 315-378 and determine whether the candidate compound is able to simultaneously form non-covalent interactions with two or more of Leu315, Ser341, Glu342, Lys343, Phe346, Lys347, Val350, Ser352, Ile354, Lys369, Ile371, Glu372, Phe378 and Thr373. A candidate compound that is able to form said interactions is predicted to modulate the aggregation of the Tau protein or truncated form thereof. Methods using a three- dimensional structural model of at least a part of the Tau protein comprising amino acids 315-378, wherein the model is an intermediate in the aggregation process of the part of the Tau protein with a paired helical filament (PHF) are also described, as are computing systems and products.

[Continued on next page]

SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*